论文部分内容阅读
目的:探讨消栓肠溶胶囊用于高血压伴心血管危险因素患者的临床疗效。方法:86例高血压伴心血管危险因素患者随机分为观察组(n=43)与对照组(n=43),对照组患者给予常规治疗,观察组患者在对照组基础上加用消栓肠溶胶囊,对比两组患者相关药物使用率、治疗前后血压及血小板活化因子(PAF)变化、随访1年中主要心血管不良事件(MACE)发生率。结果:两组患者钙离子拮抗剂、β受体阻滞剂、血管紧张素转换酶抑制剂、血管紧张素受体抑制剂、利尿剂以及他汀类药物使用率比较均无统计学差异(P>0.05);两组治疗前SBP、DBP、PAF比较均无统计学差异(P>0.05),治疗后均显著降低(P<0.01),且治疗后观察组PAF显著低于对照组(P<0.01);治疗后1年内观察组死亡、再发心梗、靶血管血运重建等MACE发生率为4.7%,显著低于对照组的20.9%(P<0.05)。结论:消栓肠溶胶囊能够有效改善高血压伴心血管危险因素患者血小板活化程度,降低心脏不良事件发生率,改善患者预后,疗效确切,安全可靠,值得推广。
Objective: To investigate the clinical efficacy of Xiaoshuan enteric-coated capsules in patients with hypertension and cardiovascular risk factors. Methods: Eighty-six patients with hypertension and cardiovascular risk factors were randomly divided into observation group (n = 43) and control group (n = 43). Patients in control group were given routine treatment. Consumers in observation group were given hypothyroidism Enteric-coated capsules, compared with the two groups of patients drug-related rates, changes in blood pressure and platelet-activating factor (PAF) before and after treatment, follow-up of major adverse cardiovascular events (MACE) incidence. Results: There was no significant difference in the use of calcium antagonists, β blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics and statins between the two groups (P> 0.05). There was no significant difference in SBP, DBP and PAF between the two groups before treatment (P> 0.05), but after treatment the levels of PAF in the observation group were significantly lower than those in the control group (P <0.01) ); The incidence of MACE death in the observation group within one year after treatment was 4.7%, which was significantly lower than that of the control group (P <0.05). Conclusion: Xiaoshuan enteric-coated capsules can effectively improve the degree of platelet activation in patients with hypertension and cardiovascular risk factors, reduce the incidence of adverse cardiac events and improve the prognosis of patients. The effect is safe, reliable and worthy of promotion.